Yes I agree @Pharmargeddon it would appear that the trajectory is adequate with the headline "Record Sales". Interestingly the same headline was released on the 10 Jan 18 for the same quarter last FY. So the sales from that quarter to this were $2.025M compared to a predicted sales of $2.2M for this quarter both of which presumably had a QVC shopping day in that period. i'm not sure that is the uplift we were expecting as yet. This appears to be related to the fact that the full range of "Evolis Products" is not yet being offered on QVC which is noted as selling the Jo-Ju range only with a 50,000 customer base. Still a healthy sales event however the release goes on to say that the distribution to other channels is a focus so some time yet to get broader and deeper traction that is envisaged by the company. Is 50,000 user base a large number in a city of 10M people ?
Would be interesting to visualise this projection on your charts @Taurean7.
Costs still running high as noted below as estimates for this quarter. I would have liked to see manufacturing costs higher and staff/admin lower.
So the goal of profitability goes to the back end of fy 19 which was not re-iterated in this release.
Q1 4C
9. Estimated cash outflows for next quarter $A’000
9.1 Research and development (180)
9.2 Product manufacturing and operating costs (500)
9.3 Advertising and marketing (600)
9.4 Leased assets -
9.5 Staff costs (900)
9.6 Administration and corporate costs (300)
9.7 Other (provide details if material)
9.8 Total estimated cash outflows (2,480)
